Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
May 10, 2022
Assignee:
Protein Potential, LLC
Inventors:
Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Type:
Application
Filed:
June 10, 2020
Publication date:
December 3, 2020
Applicant:
Protein Potential, LLC
Inventors:
Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
June 30, 2020
Assignee:
Protein Potential, LLC
Inventors:
Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Type:
Application
Filed:
July 6, 2016
Publication date:
September 20, 2018
Applicant:
Protein Potential, LLC
Inventors:
YUN WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN